Document is current
Any future updates will be listed below
-
Authors
Petrera, Marilena
Paleari, Laura
Clavarezza, Matteo
Puntoni, Matteo
Caviglia, Silvia
Briata, Irene Maria
Oppezzi, Massimo
Mislej, Eva Mihajlovic
Stabuc, Borut
Gnant, Michael
Bachleitner-Hofmann, Thomas
Roth, Wilfried
Scherer, Dominique
Haefeli, Walter-E.
Ulrich, Cornelia M.
DeCensi, Andrea
-
Funding
Funding for this research was provided by:
ERA-NET Transcan (JTC 2013-056)
Italian Association for Cancer Research (IG 2014, Rif. 15468)
- License Information
-
More Information
Article History
Received: 28 March 2018
Accepted: 22 November 2018
First Online: 4 December 2018
Ethics approval and consent to participate
: The trial was approved in Italy by the Italian Medicines Agency (AIFA) and the local Ethical Committee (Comitato Etico Regionale della Liguria) for the enrolling site E.O. Ospedali Galliera; in Slovenia by the Republic of Slovenia National Medical Ethics Committee for the enrolling site University Medical Centre Ljubljana; in Austria by the Ethics Committee of the Medical University of Vienna for the three enrolling sites: University of Vienna, Medical University Innsbruck and Hospital Wels-Grieskirchen (Klinikum Wels-Grieskirchen GmbH). This study complies with the Declaration of Helsinki and guidelines on Good Clinical Practice (ICH E6). All patients are informed of the objectives of the study and are invited to voluntarily participate. Patients who agree to participate provide written consent that can be withdrawn at any time without consequences for further treatment. Patients will receive a copy of their rights.Both positive and negative findings will be published in accordance with the CONSORT guidelines [CitationRef removed].
: Not applicable.
: The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
